Fangzhou Jianke Builds H2H Smart Healthcare Ecosystem to Innovate Chronic Disease Management
Chronic diseases have become a major public health issue threatening the health of Chinese residents.
According to the "Report on the Nutritional Status and Chronic Diseases of Chinese Residents (2020)," in 2019, deaths attributable to chronic diseases accounted for as high as 88.5% of all deaths in China. It is projected that by 2050, with the further acceleration of population aging, this figure will exceed an alarming 90%. Behind these statistics lie the joys and sorrows of countless individual lives, as well as a manifestation of the significant pressure borne by society as a whole.
In the face of severe challenges, numerous stakeholders in the healthcare industry are actively engaged in providing continuous, professional, and refined chronic disease management services to patients. On the policy front, the "Healthy China 2030" Planning Outline explicitly identifies reducing premature mortality from major chronic diseases as a key indicator, mandates the implementation of comprehensive prevention and control strategies for chronic diseases, and aims to achieve health management for chronic diseases across the entire population and throughout the life course by 2030.
Meanwhile, the development of internet technology and the impact of the COVID-19 pandemic have accelerated the shift of users’ health consumption and consultation habits to online platforms. Moreover, the connectivity features of the internet enable equitable access to pharmaceuticals and medical services, facilitating continuous, whole-course management from hospitals to homes, thereby delivering long-term, personalized care for patients with chronic diseases.
Chronic disease management services are becoming one of the most critical components of China’s healthcare market, and internet healthcare platforms that have established early footholds are poised to seize emerging opportunities.
Since its establishment, Fangzhou Jianke Group has focused on advancing internet-based chronic disease management services, striving to become China’s largest chronic disease service platform. Over the years, the company has remained patient-centric,Established a closed-loop internet-based chronic disease management service, supported by operations including an internet hospital, a one-stop chronic disease service center, a new media center, and an online pharmacy.
Fangzhou Jianke Group has successively established strategic partnerships with multiple pharmaceutical companies, including Santen Pharmaceutical, Menarini, Zeltzer Pharma, and Novartis. Through the joint efforts of its numerous partners, Fangzhou Jianke Group has built a comprehensive chronic disease management platform covering cardiovascular and cerebrovascular diseases, diabetes, bone and joint disorders, men’s health, psychiatry, respiratory diseases, gastroenterology, oncology, gynecology, and dermatology. The group has also successfully established and operates three specialized health service centers: the Chronic Inflammatory Bowel Disease Center, the Men’s Health Service Center, and the Dermatology Health Service Center.
In the realm of digital innovation services, Ark Health Group has launched an innovative "service + content" model based on years of exploration to uncover patients' needs for medications and services, while also helping pharmaceutical companies enhance user brand recognition.
In terms of services,Fangzhou Jianke Group leverages its internet hospital and chronic disease management centers to precisely understand patients’ medication needs and feedback during treatment. By establishing an online business closed loop—encompassing digital prescription circulation, e-pharmacies, and innovative payment solutions—the group enhances drug accessibility. This enables patients to complete the entire process of online consultation, follow-up visits, and medication purchase from home, thereby improving medication adherence and enhancing the quality of life for patients with chronic diseases.
It is reported that Jingtai Hospital Internet Hospital, Fangzhou Internet Hospital, Fangzhou Jianke Hospital Internet Hospital, and the Third Division General Hospital Fangzhou Internet Hospital, all under the Fangzhou Jianke Group, have successively received approval for operation and have been gradually integrated into the medical insurance system.
In terms of content, Ark Health Group has differentially launched “Ark MedChat” and integrated new media marketing services.
With the development of internet-based healthcare and the growing public emphasis on personal health, users seek a clear understanding of their medical conditions and, under professional guidance, the ability to evaluate and participate in selecting their treatment plans. In this process, technologies such as the internet and digitalization are needed to reduce the complexity of interpreting medical information, enabling users to understand treatment options more quickly, conveniently, and comprehensively, thereby accelerating accurate decision-making.
“Ark Health Talk” is a health science popularization platform launched by Ark Health Group, dedicated to serving patients with chronic diseases. It delivers a vast amount of professional health information through short videos, illustrated articles, comics, audio content, and Q&A sessions, meeting the needs of chronic disease patients for authoritative health education and enabling them to efficiently access accurate information in the current era of information overload.
Meanwhile, Fangzhou Jianke’s New Media Service Center has established a top-tier matrix of health-focused media IPs characterized by rapid growth and comprehensive coverage, with the aim of building an authoritative platform for popular science knowledge in the field of internet healthcare. Through omni-media channels, Fangzhou Jianke Group precisely delivers professional health education content, including illustrated articles and other medical information provided by its platform, to end-users (C-side). This initiative enhances chronic disease patients’ understanding of diagnosis and treatment, facilitating their transition from passive treatment adherence to active participation in personal health services.
This innovative “service + content” model not only facilitates better doctor-patient communication but also narrows the information gap for patients, thereby enhancing their experience in seeking medical care and using medications.
In the field of internet-based medical services, Fangzhou Jianke Group has proposed the H2H (Hospital to Home) model—a smart healthcare ecosystem spanning from hospitals to homes., advocating the gradual extension of medical services, chronic disease management, patient-provider education, and pharmaceutical services from hospitals to patients’ homes, thereby enabling home-based disease care, improving patients’ healthcare experience, and enhancing the timeliness of medical services and the accessibility of pharmaceutical services.。
In patient services,Establishing relational connections through technological means such as AI applications, knowledge graphs, cloud computing, and blockchaininnovation across four key dimensions—clinical segments, interactive diagnosis and treatment models, pharmaceutical services, and disease course management—to establish a more stable “acquaintance-style” doctor-patient relationship and facilitate continuous communication between doctors and patients.
Meanwhile, to more effectively deliver health services and innovative treatment regimens to patients, Fangzhou Jianke Group’s physician assistant team, in-house physician team, and specially appointed medical expert advisory team will provide chronic disease patients with exclusive, personalized services that incorporate the features of professional online family doctors. This will be achieved through a standardized management service system, aiming to consolidate therapeutic outcomes, enhance patient adherence, and thereby reduce or delay the onset of complications.
In terms of physician services,Leveraging patient diagnosis and treatment data retained on the platform, physicians formulate targeted care plans based on changes in patients' conditions. This approach not only improves medication adherence but also facilitates a shift in patient management from treatment-oriented to prevention-oriented scenarios and services. Meanwhile, the application of artificial intelligence technologies assists physicians in diagnosis, thereby enhancing clinical efficiency.
By serving both physicians and patients, Ark Health can establish broader and deeper connections among pharmaceutical companies, physicians, and patients, delivering cutting-edge academic knowledge to physicians and providing patients with comprehensive drug information and innovative chronic disease management solutions.
Currently, Fangzhou Jianke Group has established five major business lines: internet hospitals, pharmaceutical services, chronic disease management, innovative payment solutions, and an omni-media service center, thereby constructing a patient-centric “physician–drug–patient–insurance–knowledge” integrated smart healthcare ecosystem.Furthermore, Ark Health Group also plans to collaborate in the areas of pharmaceutical supply chain management, patient-physician education, health big data, and digital therapeutics.Explore integrated pharmaceutical and healthcare services, including medication safety and doctor-patient education.
Technology is a tool, not an end in itself. Thanks to the iterative development of digital technologies such as the internet, big data, and AI, the healthcare industry has accelerated its pace, optimizing patients’ care experiences, physicians’ diagnostic and treatment efficiency, and drug accessibility. However, innovation in chronic disease management requires time to accumulate before significant results can be achieved. It would be prudent to extend greater patience and confidence to internet-based innovators, allowing them to devote more energy to exploring optimal solutions in healthcare. As an outstanding representative in this field, the future moves of Fangzhou Jianke Group are certainly worth anticipating.